C22 Glucosylceramide-d4 (d18:1/22:0-d4)
(Synonyms: N-Docosanoyl-glucopsychosine-d4, N-Docosanoyl-β-glucosylsphingosine-d4, GluCer(18:1/22:0-d4), N-C22:0-Glucocerebroside-d4, C22 Glucosylceramide-d4, Glucosylceramide-d4 (d18:1/22:0-d4)) 目录号 : GC46999A neuropeptide with diverse biological activities
Cas No.:2738376-81-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C22 Glucosylceramide-d4 is intended for use as an internal standard for the quantification of C22 glucosylceramide by GC- or LC-MS. C22 Glucosylceramide is an endogenous glucosylceramide.1,2,3 Glucosylceramides are major constituents of skin lipid membranes where they play a role in maintaining the water permeability barrier. They are precursors in the synthesis of lactosylceramide , as well as oligoglycolipids and gangliosides. Phospholipase A2 (PLA2) type XIIA knockdown increases C22 glucosylceramide expression in rat brain.3 It is also increased in the brain, but not the liver or spinal cord, of mice fed a methionine-restricted diet.2 In human athletes, plasma levels of C22 glucosylceramide increase during exercise and return to basal levels during recovery.1 [Matreya, LLC.]
1.Bergman, B.C., Brozinick, J.T., Strauss, A., et al.Serum sphingolipids: Relationships to insulin sensitivity and changes with exercise in humansAm. J. Physiol. Endocrinol. Metab.309(4)E398-E408(2015) 2.JovÉ, M., Ayala, V., RamÍrez-NÚÑez, O., et al.Specific lipidome signatures in central nervous system from methionine-restricted miceJ. Proteome Res.12(6)2679-2689(2013) 3.Ee, S.-M., Lo, Y.-L., Shui, G., et al.Distribution of secretory phospholipase A2 XIIA in the brain and its role in lipid metabolism and cognitionMol. Neurobiol.50(1)60-75(2014)
| Cas No. | 2738376-81-1 | SDF | |
| 别名 | N-Docosanoyl-glucopsychosine-d4, N-Docosanoyl-β-glucosylsphingosine-d4, GluCer(18:1/22:0-d4), N-C22:0-Glucocerebroside-d4, C22 Glucosylceramide-d4, Glucosylceramide-d4 (d18:1/22:0-d4) | ||
| Canonical SMILES | O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(CCCCCCCCCCC([2H])([2H])C([2H])([2H])CCCCCCCCC)=O)[C@@H]1O | ||
| 分子式 | C46H85D4NO8 | 分子量 | 788.2 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2687 mL | 6.3436 mL | 12.6871 mL |
| 5 mM | 0.2537 mL | 1.2687 mL | 2.5374 mL |
| 10 mM | 0.1269 mL | 0.6344 mL | 1.2687 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet